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MicroRNAs (miRNAs) are small noncoding RNAs that can function as either powerful tumor promoters or suppressors
in numerous types of cancer. The ability of miRs to target multiple genes and biological signaling pathways has
created intense interest in their potential clinical utility as predictive and diagnostic biomarkers, and as innovative
therapeutic agents. Recently, accumulating preclinical studies have illustrated the feasibility of slowing tumor
progression by either overexpressing tumor suppressive miRNAs, or by neutralizing the activities of oncogenic miRNAs
in cell- and animal-based models of cancer. Here we highlight prominent miRNAs that may represent potential
therapeutic targets in human malignancies, as well as review current technologies available for inactivating or restoring
miRNA activity in clinical settings.
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Introduction
The war against cancer commenced in 1971 with the en-
actment of the National Cancer Act and continues un-
abated today against this most common killer of American
men and women between the ages of 40-79 [1]. Indeed,
the American Cancer Society estimates that 25% of all
deaths in the United States can be directly attributed to
cancer, which is anticipated to account for nearly 600,000
deaths and 1.7 million new invasive cancer cases in 2014.
Despite this rather bleak outlook, the collective efforts of
science and medicine have nevertheless dramatically re-
duced the annualized cancer death rate by 20% over the
last two decades, thereby sparing the lives of more than 1.3
million Americans [1]. Building upon this success will re-
quire the development of new diagnostic and prognostic
tests, as well as the creation of novel targeted chemother-
apies derived from enhanced knowledge of the molecular
mechanisms coupled to tumorigenesis and metastatic
progression.* Correspondence: molly.taylor@astrazeneca.com;
william.schiemann@case.edu
1Oncology iMed, AstraZeneca R & D, Room 33F83/7 Mereside, Alderley Park,
Macclesfield SK10 4TG, UK
2Case Comprehensive Cancer Center, Case Western Reserve University,
Wolstein Research Building, Room 2131, 2103 Cornell Road, Cleveland, OH
44106, USA
© 2014 Taylor and Schiemann; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.The central dogma of molecular biology states that the
transfer of genetic information within cells transpires se-
quentially from DNA to RNA to proteins, whose coding
sequences comprise a paltry 1.5-2% of the human genome
[2,3]. Although genetic and epigenetic aberrations that
occur in components of the central dogma clearly elicit
disease development in humans, recent findings also point
to a prominent role for non-protein-coding regions of the
genome in regulating cell and tissue homeostasis, as well
as in contributing to the formation of human tumors. In-
cluded amongst the various classes of noncoding RNAs
are members of the PIWI-interacting RNA (piRNA) fam-
ily, the small nucleolar RNA (snoRNA) family, the large
intragenic noncoding RNA (lincRNA) family, the long
noncoding RNA (lncRNA) family, and the transcribed
ultraconserved regions (T-UCR) family of the lncRNAs
[3-5]. However, the best characterized and most exten-
sively studied class of noncoding RNAs belong to the family
of microRNAs (miRNAs), which play essential functions
during embryogenesis and tissue development, and during
cell differentiation, proliferation, and survival [4,5]. As a
group, miRNAs are small (17-27 nucleotides) noncoding
RNAs that govern gene expression in a post-transcriptional
manner by binding directly to the 3′UTRs of target
mRNAs, thereby repressing their translation or inducing
their degradation [6]. In doing so, miRNAs have beend Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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cells, and as being robust tumor promoters in developing
and progressing carcinomas [7,8]. Moreover, miRNAs are
frequently located at fragile genome sites or regions that
are frequently amplified or deleted in human cancers [9].
Indeed, emerging evidence indicates that miRNAs func-
tion as a molecular rheostats that serve in fine-tuning cell
signaling pathways [10,11], doing so by modulating the ex-
pression of large numbers of genes and, consequently,
impacting the flux through essential regulatory nodes of
vast signaling networks. These functional characteristics
underlie the belief that targeting and manipulating either
the expression or activity of miRNAs may provide novel
inroads to treat human cancers, a supposition currently
being evaluated in phase I clinical trials for MRX34 (a
miR-34 mimetic) against late-stage hepatocellular carcin-
omas and a variety of lymphomas ([5]; ClinicalTrials.gov
number, NCT01829971), and in phase II clinical trials for
miR-122 antagonists against hepatitis ([12]; ClinicalTrials.
gov number, NCT01200420). In the succeeding sections,
we review recent findings pertaining to how miRNA ex-
pression transpires in normal cells, and to how these
events become dysregulated in malignant cells, leading to
their acquisition of metastatic and chemoresistant pheno-
types. Finally, we discuss current therapeutic strategies
aimed at targeting inappropriate miRNA expression and
activity in developing and progressing human carcinomas.
miRNA biogenesis
miRNAs are transcribed in the nucleus by the actions of
RNA polymerases II or III to produce a long primary
miRNA transcript (pri-miRNA), which subsequently as-
sociates with the Drosha-microprocessor complex that
houses the (i) RNase III enzyme, Drosha, (ii) DGCR8
(DiGeorge critical region 8), and (iii) RNA helicases p68
and p72 (see [13]). In addition, the KH-type splicing
regulatory protein (KSRP) can also associate with the
microprocessor complex to regulate the biogenesis of a
subset of miRNAs operant in regulating cell differenti-
ation, proliferation, and survival [14]. Endonucleolytic
cleavage of pri-miRNAs by the microprocessor complex
leads to formation of precursor miRNAs (pre-miRNA),
which exist as hairpin loop structures of ~60-70 nucleo-
tides in length that are exported from the nucleus by the
actions of Exportin-5, with assistance from Ran-GTPases
[15]. Upon gaining access to the cytoplasm, the pre-
miRNA is further processed and cleaved by the Dicer/
TRBP (Tar RNA-binding protein) complex to produce a
mature ~21 nucleotide RNA duplex [16], which together
with Argonaute (Ago2) proteins is loaded into the RNA-
induced silencing complex (RISC). Interestingly, the
orientation of mature miRNAs as they are loaded into
RISC complexes is governed by their 5′-antisense ends,
which possess enhanced flexibility and lower internalstabilities that facilitate miRNA unwinding and strand
retention by active RISCs [17]. Finally, the extent of se-
quence complementarity between the 5′-seed region of
the loaded miRNA with that of its target mRNA 3′UTR
largely dictates whether individual mRNAs are inacti-
vated via cleavage, translational repression, or deadeny-
lation (Figure 1; [13]). As will be discussed below, recent
studies clearly demonstrate the importance of oncogenic
signaling systems to impinge upon multiple steps of
the miRNA biogenesis pathway, resulting in the aber-
rant expression and activity of miRNAs during tumori-
genesis [18,19].
Aberrant miRNA biogenesis in carcinomas
Although major progress has been achieved in terms of
understanding the fundamental mechanisms whereby
miRNAs are synthesized and processed, considerably
less knowledge exists regarding the specific intracellular
pathways and effector molecules coupled to the regula-
tion of miRNA biogenesis. Recently, administration of
either transforming growth factor-β (TGF-β) or bone
morphogenetic protein-4 (BMP-4) to pulmonary artery
smooth muscle cells (PASMCs) was observed to dramat-
ically elevate their levels of mature miR-21 independent
of any alterations in the transcription of pre-miR-21
[20], suggesting that these multifunctional cytokines
drive the processing of miR-21, not its transcription. Ac-
cordingly, receptor-regulated Smad transcription factors
for TGF-β (Smads 2 and 3) and BMP-4 (Smads 1, 5, and
8) were found to associate with Drosha complexes by
interacting with the RNA helicase, p68 [20], a reaction
dependent upon the presence the Smad-binding elements
(SBEs) located in the stem regions of ~20 pre-miRNAs
known to be responsive to TGF-β/BMP-4 stimulation [21].
Indeed, engineering SBE sequences into stem loop struc-
tures was sufficient to confer TGF-β/BMP-4-mediated
processing of pre-miRNAs to yield their mature products
(Figure 1; [21]). It should be noted that the ability of tran-
scription factors to drive miRNA processing is not unique
to TGF-β/BMP-regulated Smads, but is instead a wide-
spread phenomenon as evidenced by the fact that ~45% of
all pre-miRNAs harbor one or more consensus binding
sites for transcription factors [22]. Indeed, similar to
Smads, the tumor suppressor p53 has also been shown to
interact with the Drosha complex through p68, resulting
in enhanced Drosha processing of pre-miRNAs coupled
to DNA damage responses and anticancer activities
(e.g., miR-16-1, miR-143, miR-145; [23]). Additionally,
hyperactivation of the Ras/ERK1/2, PI3K/Akt, and ATM/
DNA damage pathways are commonplace in carcinoma
cells and have recently been shown to promote the
phosphorylation of TRBP, which enhances Dicer cleavage
activity, and of KSRP, which enhances pri-miRNA pro-
cessing reactions [24-27]. Thus, one mechanism whereby
Figure 1 miRNA biogenesis. miRNAs are transcribed by RNA polymerase II or III (Pol II/III) to produce primary transcripts (pri-miRNAs), which
are subsequently processed and cropped via the actions of the Drosha-DGCR8 complex, which together with the RNA helicases p68 and p72
generate the formation of precursor miRNAs (pre-miRNAs). Activation of the TGF-β, Akt/PI3K, and p53 signaling systems have all been shown to
promote the processing of specific pri-miRNAs, while stimulation of the ER-α signaling system is capable of repressing pri-miRNA processing.
Once processed, pre-miRNAs hairpins are exported from the nucleus by exportin-5 (XPO5)-RanGTPase complexes, and are subsequently cleaved
by Dicer:TRBP complexes, thereby producing mature oligonucleotide duplexes. The rate at which Dicer cleaves pre-miRNAs is greatly enhanced
by the phosphorylation of TRBP by Erk1/2. At the completion of pre-miRNA cleavage, Dicer serves with Argonaute (Ago) 2 in loading mature
miRNAs into RNA-induced silencing complexes (RISCs), thereby silencing target mRNA expression through mRNA cleavage, translational repression,
or deadenylation. Hypoxic conditions resulting in EGFR activation have been shown to induce the phosphorylation of Ago2, leading to diminished
maturation reactions of select miRNAs.
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and metastatic progression transpires through upregulated
miRNA processing and its associated inactivation of
tumor suppressing genes and pathways.
In stark contrast to aforementioned mechanisms that
underlie the increased processing of miRNAs, recent find-
ings also observed significant reductions in miRNA pro-
cessing in response to oncogenic signals. For instance,
estradiol-mediated activation of estrogen receptor-α (ER-α)
drives the association of this steroid receptor with p68,
resulting in widespread inhibition of pri-miRNAs by
Drosha complexes [28]. Likewise, hypoxic stress enablesthe epidermal growth factor receptor (EGFR) to phos-
phorylate Ago2 and prevent its binding to Dicer,
thereby inhibiting the processing and maturation of
tumor suppressive pre-miRNAs (e.g., miR-31, miR-192,
and mir-193-5p; [29]). Future studies need to further elu-
cidate the molecular mechanisms whereby oncogenic
signaling pathways converge on the miRNA biogenesis
network, particularly with respect to defining the se-
quence and specificity of these aberrant interactions,
which may aid in discovering novel miRNA-based tar-
geted therapies to alleviate carcinoma development and
metastatic progression.
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The “Hallmarks of Cancer” were eloquently proposed by
Hanahan and Weinberg to describe the essential features
ingrained in the physiology of all malignant cells that
drives their growth and dissemination. Indeed, included
amongst the traits displayed by all carcinoma cells is
their ability to (i) activate proliferative and replicative
immortality programs, while simultaneously inactivating
antigrowth programs; (ii) resist apoptotic programs; and
(iii) stimulate angiogenic, invasive, and metastatic pro-
grams [30,31]. Importantly, miRNAs play active roles in
modulating all of these physiological processes in carcin-
omas, typically acting on multiple pathways and pro-
grams to elicit disease development. Identifying and
understanding how miRNAs regulate the balance of and
flux through these signaling systems may provide novel
opportunities to design and implement miRNA-directed
therapies to treat human malignancies. In the succeeding
sections, we highlight a variety well-characterized and es-
sential miRNAs operant in driving tumorigenesis based
on their classification as oncomiRs (i.e., tumor promoting
miRNAs), tumor suppressive miRNAs, or metastamiRs
(i.e., metastasis promoting miRNAs) (Table 1). It should
be noted that this discussion is by no means comprehen-
sive, and as such, readers desiring more extensive sum-
maries are directed to several recent reviews [5,32,33].
oncomiRs
miR-17-92 cluster
The best characterized oncomiR is the polycistronic
miR-17-92 (also known as oncomiR-1), whose expres-
sion from chromosome 13 is driven by c-Myc and re-
sults in the production of six mature miRNAs, namely
miR-17-5p, miR-18a, miR-19a, miR-20a, miR-19b-1, and
miR-92a-1 [34]. Additionally, two miR-17-92 paralogs
have been identified: (i) the miR-106a-363 cluster, which
is located on the X chromosome and houses miR-106a,
miR-18b, miR-20b, miR-19b-2, miR-92a-2, and miR-363,
and (i) the miR106b-25 cluster, which is located on
chromosome 7 and houses miR-106b, miR-93, and miR-25
[35]. Consistent with its designation as an oncomiR, the lo-
cation of the miR-17-92 cluster on chromosome 13 is
found within a genomic region that is frequently amplified
in a variety of human tumors, including diffuse B-cell, fol-
licular, and Burkit’s lymphomas, and lung carcinomas
[36]. Initial studies demonstrated that overexpression of
mir-17-92 in an Eμ-Myc transgenic mouse model of
Burkit’s lymphoma was sufficient to accelerate the tumori-
genic process by suppressing apoptosis [34]. Indeed, the
anti-apoptotic effects of this oncomiR cluster in haemato-
poietic malignancies can be ascribed to its targeting of the
Bim and PTEN tumor suppressors [37-39]. With respect
to solid tumors, the miR-17-92 cluster has been shown to
induce proliferation, as well as augment angiogenesisthrough its ability to target p21 [40,41], thrombospondin-1
(TSP1), and connective tissue growth factor (CTGF;
[42]). Along these lines, the miR-106b-25 cluster was
observed to drive mammary tumorigenesis and epithelial-
mesenchymal transition (EMT) programs by targeting the
inhibitory Smad, Smad7, thereby enhancing oncogenic
TGF-β signalling [43]. Although the exact physiological
function and degree of functional redundancy possessed
by individual miRNAs of the mir-17-92 cluster remains to
be fully elucidated, recent evidence indicates that these
miRNAs do in fact exhibit a combination of unique and
overlapping functions that coalesce in regulating embryo-
genesis and tissue development, as well as in driving
tumorigenesis [39]. Future studies clearly need to expand
our understanding of which mRNAs are targeted by the
miR-17-92 cluster and its paralogs, thereby providing po-
tential inroads for the development of novel therapeutics
capable of alleviating the oncogenic activities of these po-
tent oncomiRs.
miR-21
Although miR-21 was originally identified as an onco-
miR in glioblastomas [44], subsequent large-scale miRNA
expression profiling analyses of 540 tumors spanning 6
distinct types of cancer (e.g., lung, breast, stomach, pros-
tate, colon, and pancreas) demonstrated that miR-21 was
upregulated in all tumor cohorts [45]. More recently, up-
regulated miR-21 expression has also been detected in
lymphoid malignancies, including chronic lymphocytic
leukemia, diffuse large B cell lymphoma, and acute mye-
loid leukemia (see [46]). Mechanistically, hyperactivation
of the Ras/MAP kinase and NF-κB signaling systems in
carcinomas elicits transcription of pri-miR-21 [47], whose
processing to maturity is dramatically enhanced by the
TGF-β signaling system [20]. Additionally, robust miR-21
expression has been observed to target a variety of essen-
tial tumor suppressors, including PTEN, p63, PDCD4,
and RECK, which serve in promoting the proliferation,
survival, and metastasis of carcinomas, as well as in
driving their acquisition of chemoresistant phenotypes
[46,47]. Clinically, elevated expression of miR-21 is a
negative predictor for disease-free survival in patients
with cancers of the breast or lung [48,49]. Collectively,
these findings illustrate the profound ability of a single
miRNA to target multiple oncogenic signaling nodes,
resulting in global dysregulation of gene expression net-
works in carcinoma cells.
miR-155
miR-155 was first identified as an oncomiR in B cell
lymphomas and chronic lymphocytic leukemias where it
functions to accelerate Myc-mediated lymphomagenesis
[50,51]. More recently, miR-155 also appears to be prom-
inently upregulated in solid tumors, including those of the
Table 1 Identity and function of cancer-associated miRNAs
microRNA
Disease setting Targets Hallmark (s) of cancer
oncomiRs
miR-17 ~ 92 Family Lymphoma and some solid tumors [36] PTEN [37,38], Bim [7,37], p21 [40,41],
TSP1 [42], CTGF [42]
Resisting cell death
Sustaining proliferative signaling, and inducing angiogenesis
miR-21 Glioblastoma [44], breast, colon, lung, pancreas, prostate,
chronic lymphocytic leukaemia, Diffuse Large B-Cell
Lymphoma, acute myeloid leukaemia and others [45,46]
PTEN, p63, PDCD4, and RECK [46] Sustaining proliferative signaling, resisting cell death,
activating invasion and metastasis
miR-155 Lymphoma [50,51], breast, colon, lung, pancreatic, and
thyroid cancer [52]
RhoA [53], SOCS1 [54], FOXO3a [55] Sustaining proliferative signaling, resisting cell death,
activating invasion and metastasis
Tumor suppressor miRs
miR-15a ~ 16-1 CLL [56], multiple myeloma, mantle cell lymphoma, and
prostate cancers [57]
Bcl2, cyclin D1, and WNT3A [59] Evading growth suppressors, Resisting cell death
let-7 Lung [61], colon, breast, and ovarian cancers [62] Ras [66], HMGA2 [67], c-Myc [65] Evading growth suppressors
miR-29 Family Lung cancer, melanoma and myeloid leukemia [75] CDK6 [70,71], Ppmid [68], osteonectin
[72], Mcl1 [73], Bcl2 [74], DNMT3a [75],
and extracellular matrix genes [76].
Sustaining proliferative signaling, Enabling replicative
immortality, Resisting cell death
miR-34 Breast, lung, colon, kidney, bladder, pancreatic cancer,
and melanoma [84]
Bcl2, cyclin D1, Cyclin E2, CDK4, CDK6,
c-Myc , MET, N-Myc, and SIRT1 [78-83]
Resisting cell death, Evading tumor suppressors, Enabling
replicative immortality.
metastamiRs
miR-200 Family Breast cancer [91,92] Zeb1, Zeb2 [93], and Sec23a [95] Activating invasion metastasis
miR-9 Breast [96] and colon [98] cancer E-cadherin [96], LIFR, Cyclin D1,
and Ets1 [97,98]
Activating invasion metastasis
miR-31 Breast cancer [99] ITGA5, RDX, RhoA and WAVE3
[100,101]
Activating invasion metastasis
miR-10b Breast [102,103] and esophageal cancer [104] HOXD10 [102] Activating invasion metastasis
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155 transcription is induced by TGF-β, interferon-γ
(IFNγ), and interleukin-6 (IL-6) and influences numerous
cancer cell signaling pathways to promote tumorigenesis.
For instance, by targeting the Rho GTPase, RhoA, miR-
155 drives the dissolution of tight junctions that occur
during EMT programs and breast cancer invasion stimu-
lated by TGF-β [53]. Likewise, miR-155 also targets and
downregulates the expression of the tumor suppressor
SOCS1 (suppressor of cytokine signaling 1), leading to
constitutive activation of the proto-oncogene STAT3 and
its ability to induce inflammatory and proliferative pheno-
types in mammary tumors [54]. Finally, miR-155 negates
apoptotic signals and enhances cancer cell survival by
repressing the expression of FOXO3a, thereby suppressing
the expression of the pro-apoptotic proteins PUMA, Bim,
FasL, and TRAIL [55].
Tumor suppressive miRNAs
miR-15a and miR-16-1 cluster
The miR-15a and miR-16-1 cluster of miRNAs were ini-
tially identified as the most frequently downregulated
collection of miRNAs in chronic lymphocytic leukemias
[56], an event that also occurs in a subset of multiple
myelomas, mantle cell lymphomas, and prostate cancers
[57]. Indeed, engineering human MEG-01 chronic mye-
logenous leukemia cells to overexpress miR-15a~16-1
dramatically suppressed their tumor forming ability
when xenografted into nude mice [58]. Interestingly,
genome-wide transcriptome profiling analyses indicate
the miR-15a~16-1 cluster directly or indirectly regulates
as much as 14% of the human genome, particularly for
mRNAs housing AU-rich elements (AREs) [58]. These
analyses also identified a signature of 60 genes whose ex-
pression is downregulated by the miR-15a~16-1 cluster,
which preferentially targets genes operant in activating cell
cycle progression and survival pathways [58]. Along these
lines, intratumoral delivery of miR-15a and miR-16-1 to
prostate tumor xenografts induced their regression via
apoptosis programs that commenced following miRNA-
directed downregulation of Bcl-2, cyclin D1, and WNT3A
[59]. Collectively, these findings highlight the potent tumor
suppressing activities mediated by restoration of the
miR-15a~16-1 cluster.
Let-7 family
The let-7 family of miRNAs was originally discovered as
negative regulators of cell cycle progression and inducers
of terminal differentiation in C. elegans, and is com-
prised of 11 homologous miRNAs, including let-7a-1,
let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-1,
let-7f-2, let-7g, and let-7i [60]. Initial evidence linking
the expression of let-7 family members to the process
of tumor suppression was obtained in studies of lungcarcinomas, which were determined to house significantly
reduced expression of let-7 as compared to adjacent nor-
mal tumor tissues, an event correlated with diminished
overall survival of lung cancer patients [61]. Subsequent
studies have clearly established reduced let-7 expression
to coincide with the development of cancers of the
colon, breast, and ovary [62]. Indeed, overexpression of
let-7 miRNAs in breast cancer tumor-initiating cells
(TICs) dramatically reduced their ability to proliferate and
form mammospheres, as well as enhanced their differenti-
ation status. More importantly, these same let-7 manipula-
tions significantly inhibited the growth and metastasis of
breast cancer TICs in mice, doing so via let-7-mediated
targeting of H-Ras, which negatively impacted TIC self-
renewal, and HMGA2, which positively impacted TIC
differentiation status [63]. Likewise, restoring let-7 expres-
sion in lung carcinoma cells reinstated their sensitivity to
radiotherapy in vitro, while similarly enhanced or reduced
expression of let-7 in C. elegans elicited sensitivity or re-
sistance, respectively to radiation-induced cell death [64].
Functionally, oncogenic activation of c-Myc represses let-
7 expression [65], while the converse scenario involving
the elevated expression and activity of let-7 in human ma-
lignancies elicits downregulation of Ras family members
[66], HMGA2 [67], and c-Myc [65], thereby suppressing
the development, progression, and therapeutic resistance
of human tumors.
miR-29 family
The miR-29 family contains three members, miR-29a,
miR-29b, and miR-29c, all of which are transcriptionally
induced by p53 [68] and repressed by c-Myc, NF-κB, and
TGF-β signaling (see [69]). Functionally, miR-29 serves to
reduce cell proliferation by targeting CDK6 [70,71], to in-
duce cell senescence or differentiation by targeting Ppmid
[68] or osteonectin [72], respectively, and to stimulate cell
apoptosis by targeting Mcl1 and Bcl2 [73,74]. Additionally,
miR-29 family members have also been observed to target
the methyltransferase, DNMT3, leading to hypomethylated
promoter regions of a variety of tumor suppressor genes in
cancer of the lung, skin, and myeloid compartment [75].
Finally, expression levels of the miR-29 family are inversely
correlated with the EMT status of carcinomas, presumably
due to the ability of this miRNA family to target extracellu-
lar matrix (ECM) proteins operant in driving carcinoma
cell migration and metastasis [76]. Thus, in addition to its
role in countering malignant transformation, future studies
also need to elucidate the extent to which expression of
the miR-29 family also functions to suppress the metastatic
progression of late-stage carcinomas.
miR-34 family
miR-34a and miR-34b/c represent the most highly upreg-
ulated miRNAs induced by the tumor suppressor, p53
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press the growth and metastasis of tumors by promoting
apoptosis, cell cycle arrest, and senescence, doing so by
targeting and downregulating the expression of oncogenic
effectors, including Bcl2, cyclins D1 and E2, CDKs 4 and
6, c-Myc, MET, N-Myc, and SIRT1 [78-83]. Additionally,
miR-34 expression is inactivated through epigenetic
methylation of its promoter, a reaction that dominates
over its transactivation by p53 and occurs in a variety of
human malignancies, including those arising in the skin
(63%), bladder (33%), lung (29%), breast (25%), kidney
(21%), pancreas (16%), and colon (13%) [84]. Likewise, loss
of miR-34 expression in prostate cancers has been linked
to their acquisition of chemoresistant phenotypes [80].
Collectively, these findings suggest that developing and
implementing novel measures capable of re-expressing
miR-34 in human carcinomas may provide a unique ap-
proach to alleviate metastatic progression and disease
recurrence.
MetastamiRs
The acquisition of metastatic phenotypes by developing
carcinomas represents the greatest barrier to effective
treatment and long-term survival of cancer patients, of
which ~90% succumb to the presence of incurable pri-
mary and recurrent metastases [85,86]. The intractability
of metastases likely reflects the complex cascade and
series of events necessary for carcinoma cells to dissemin-
ate and thrive beyond the confines of the primary tumor.
Indeed, navigating the metastatic cascade requires carcin-
oma cells to (i) invade into and migrate through the sup-
porting tumor stroma; (ii) intravasate into and traverse
throughout the lymph and circulatory systems; and (iii)
extravasate out of the circulation and ultimately infiltrate
and colonize the secondary organ site [85-87]. Although a
thorough understanding of the cellular and molecular
mechanisms responsible for metastasis remain to be eluci-
dated, recent findings have nevertheless identified a sub-
class of miRNAs whose expression is highly associated
with the acquisition of metastatic phenotypes. Indeed,
the importance miRNAs to drive metastasis is highlighted
by the fact that diminished Dicer function elicited by
miR-103/107 targeting was found to significantly enhance
the metastatic activity of mammary tumors [88]. In the
succeeding sections, we will discuss a variety of metastasis-
related miRNAs, which are referred to as “metastamiRs”
and endowed with either metastasis promoting or sup-
pressing activities [89,90].
miR-200 family
The miR-200 family is comprised of 5 related miRNAs,
namely miR-200a, miR-200b, miR-200c, miR-141, and
miR-429. Functionally, this family serves to maintain
epithelial cell gene expression profiles, morphologies,and characteristics, thereby suppressing the acquisition
of EMT and metastatic phenotypes [91,92]. Mechanistic-
ally, miR-200 family members promote E-cadherin expres-
sion by repressing that of the master EMT transcription
factors, Zeb1 and Zeb2, which function in preventing the
production of E-cadherin transcripts [93]. Accordingly,
enforced expression of miR-200 is sufficient to alleviate
the ability of lung cancers to undergo EMT programs and,
consequently, to engage in invasion and metastatic behav-
iors in mice [94]. Interestingly, recent studies have associ-
ated metastasis-promoting activities with the expression
of miR-200 family members in the late-stages of meta-
static colonization and outgrowth, doing so by down-
regulating the expression of Sec23a and preventing its
secretion of the metastasis suppressing proteins, IGFBP4
(insulin-like growth factor-binding protein 4) and TINAGL1
(Axl receptor tyrosine kinase, tubulointerstitial nephritis
antigen-like 1) [95]. Collectively, these findings indicate
that the ability of miR-200 family members to either sup-
press (e.g., early-stage disease) or promote (e.g., late-stage
disease) metastasis transpires in a context-dependent
manner that may reflect alterations in the genetic land-
scape of developing carcinomas as they progress from
early-stages to late-stages of the disease.
miR-9
In stark contrast to members of the miR-200 family and
their indirect coupling to E-cadherin expression via Zeb1/2,
the expression of miR-9 serves to promote invasive and
metastatic phenotypes by directly downregulating the
levels of E-cadherin transcripts in mammary carcinomas
[96]. In addition to its ability to suppress the expression of
E-cadherin, miR-9 also promotes carcinoma invasion and
metastasis by targeting the leukemia inhibitory factor re-
ceptor (LIFR), leading to the inactivation of prometastatic
signals mediated by the Hippo-YAP pathway [97]. Inter-
estingly and reminiscent of the context-specific activities
of miR-200 family members, Zheng et al. [98] recently ob-
served the expression of miR-9 to be dramatically down-
regulated in gastric cancers, an event associated with their
acquisition of proliferative, invasive, and metastatic phe-
notypes. Importantly, the tumorigenicity of gastric cancers
was significantly suppressed by restoring miR-9 expression
in miR-9-deficient gastric cancers, thereby reducing the
expression of the cyclin D1 and Ets1 oncogenes [98].
Thus, future studies need to determine the contexts and
genetic backgrounds that underlie the gain or loss of
miR-9 expression in human malignancies, as well as how
these events contribute to the growth and metastatic pro-
gression of the neoplastic lesions.
miR-31
The expression of miR-31 is inversely correlated with the
metastatic capacity of more than 15 breast cancer cell
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suppressing miRNA. Accordingly, re-expression of miR-
31 in human breast cancers that lack expression of this
miRNA significantly impaired their metastatic dissemin-
ation in mice [99], doing so by inhibiting breast cancer
migration and invasion, and by sensitizing these same cells
to anoikis-mediated apoptosis [99]. Mechanistically,
miR-31 suppresses metastasis by targeting the expression
of α5 integrin (ITGA5), radixin (RDX), RhoA, and WAVE3
(WAS protein family member 3) [100,101]. Clinically, ab-
normally low miR-31 expression levels in primary breast
tumors is associated with increased metastasis and disease
relapse [99,101], indicating that miR-31 does indeed act as
a potent inhibitor of the metastatic cascade.
miR-10b
The finding that miR-10b is differentially expressed and
significantly higher in metastatic breast cancer cells as
compared to their nonmetastatic counterparts suggest
that this miRNA promotes the acquisition of metastatic
phenotypes in developing carcinomas [102,103]. Indeed,
tumor specimens obtained from breast cancer patients
demonstrated that elevated miR-10b expression was
prevalent in patients harboring metastatic disease [102].
Moreover, abnormally elevated expression of miR-10b
correlates with the appearance of high-grade malignan-
cies in the liver, pancreas, and brain [104]. Consistent
with its designation as a “metastamiR”, overexpression
of miR-10b preferentially drives the metastasis of breast
and esophageal cancers in mice without effecting the be-
haviors of the corresponding primary tumors [102,105].
Mechanistically, miR-10b expression is upregulated by
the EMT-promoting transcription factor, Twist, which
results in miR-10b-mediated suppression of HOXD10
expression and, consequently, in the upregulated expres-
sion of the cell motility and ECM remodeling genes
RhoC, uPAR (urokinase-type plasminogen activator
receptor), α3 integrin, and MT1-MMP (membrane-type 1
MMP) [102]. Finally, systemic delivery of miR-10b antago-
miRs potently inhibited the metastasis of breast cancers in
mice, an event that occurred with little-to-no measurable
toxicity [106], suggesting that inactivation of miR-10b ex-
pression and activity holds potential to prevent carcinoma
metastasis.
miR-181a
miR-181a has been shown to function as either a tumor
suppressor or a tumor promoter in a context-dependent
manner (see [107]). For instance, we recently uncovered
a novel role for miR-181a in promoting breast cancer
metastasis and showed that the expression of this metas-
tamiR correlates with the metastatic potential of breast
cancers, particularly those classified as triple-negative
(i.e., lack ER-α and progesterone receptor expression,and fail to amplify HER2) [108]. Functionally, upregulated
miR-181a expression was observed to inhibit anoikis by
targeting the pro-apoptotic protein, Bim, and to enhance
EMT programs stimulated by TGF-β [108]. Likewise,
miR-181a expression has been linked to the generation
and expansion of cancer stem cells through its ability to
target ATM [109]. Importantly, targeted inactivation of
miR-181a reduced the metastatic outgrowth of breast can-
cer cells in mice [108], a finding consistent with the dem-
onstration that high miR-181a levels correlated with a
dramatic decline in the overall survival of breast cancer
patients [108]. Along these lines, upregulated miR-181a
expression in epithelial ovarian cancers enhanced TGF-β
signaling and disease progression by targeting the inhibi-
tory Smad, Smad7, leading to the acquisition EMT, motile,
and chemoresistant phenotypes in caners of the ovary
[110]. In stark contrast, loss of miR-181a expression sug-
gestive of a tumor suppressive function has been detected
in a variety of human cancer cell lines, including those
derived from the lung and brain [107]. Although the
mechanisms responsible for eliciting discrepant miR-181a
expression profiles remains to be fully elucidated, recent
findings implicate expression of p53 as a molecular deter-
minant of miR-181a expression [107]. As such, future
studies need to better understand the relationship between
miR-181a expression and that of classical tumor suppres-
sors and promoters before undertaking the therapeutic
targeting of miR-181a to alleviate carcinoma metastasis.
Therapeutic strategies for targeting miRNAs
The small size, extreme stability, and potent biological ac-
tivities exhibited by miRNA oligonucleotides suggests that
measures capable of targeting and/or delivering miRNAs
to developing carcinomas holds great promise to alleviate
disease progression and improve overall survival rates of
cancer patients. Accordingly, the pharmacologic delivery
of miRNA oligonucleotides or viral-based miRNA expres-
sion constructs to tumors seeks limit their growth and dis-
semination via 3 general strategies: (i) inactivate the
oncogenic activities of oncomiRs; (ii) reinstate the expres-
sion of tumor suppressive miRNAs; and (iii) administer




Antisense oligonucleotides inhibit target miRNAs by an-
nealing to complementary sequences within mature
miRNAs, thereby inducing their degradation or blocking
their function. The inherent instability of single-stranded
oligonucleotides has been circumvented by the incorpor-
ation of chemical modifications designed to increase the
stability, binding affinity, and specificity of newly synthe-
sized single-stranded oligonucleotides [111]. For instance,
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of nucleotides [112], while adding sulphur atoms to form
phosphorothiote bonds further increases nucleotide stabil-
ity, but often at the expense decreasing binding affinity
[113]. More recently, 2′-O-methyoxyethyl (2′-MOE) and
2′-Fluoro (2′-F) modifications have been shown to pro-
vide superior binding affinity as compared to 2′-O-methyl
modifications [114,115]. Thus, selective modification of
both the 2′ sugar position and phosphodiester bonds is
necessary to obtain optimal nucleotide stability and affin-
ity. Indeed, single-stranded phosphorothioate-linked RNA
analogues that contain 2′-O-methyl-modified cholesterol-
conjugated nucleotides have been shown to be effective in
specifically targeting miR-122 in the liver for 23 days fol-
lowing a single intravenous injection of the ‘miR-122
antagomiR’ [113].
Locked nucleic acid (LNA) constructs
Locked nucleic acid (LNA) constructs represent a novel
class of nucleic acid analogs characterized by the pres-
ence of a “locked” ribose ring generated by the forma-
tion of a methylene bridge between the 2′-O atom and
the 4′-C atom [116]. Interestingly, antisense compounds
that house a “locked” configuration display several desir-
able features as compared to traditional “antagomiR”
chemistry, including (i) increased binding affinity against
complementary single stranded RNA molecules, (ii) en-
hanced discrimination against base mismatches, and (iii)
improved efficiency of target miRNA knockdown and in-
activation [116]. More recently, LNA chemistry served
as the foundation during the synthesis of the anti-miR-
122 agent developed by Santaris Pharma (SPC3649),
which is highly effective in downregulating miR-122
levels in the liver in non-human primates (African Green
Monkeys; [117]), and in treating chronic HCV infection in
chimpanzees [118]. In both scenarios, administration of
SPC3649 was demonstrated to possess low toxicity pro-
files, indicating that LNA molecules are well-tolerated
in vivo and, consequently, may represent ideal agents de-
signed to alleviate the tumor promoting activities of onco-
miRs in cancer patients.
miRNA sponges and masks
miRNA sponges serve as competitive inhibitors by bind-
ing complementary miRNAs, thereby ‘soaking up’ avail-
able oncomiR reservoirs. Typically, miRNA sponges are
retroviral vectors engineered to house multiple tandem
miRNA binding sites whose expression is driven from a
strong promoter, resulting in the supraphysiological ex-
pression of desired “antagomiRs”. At present, stable ex-
pression of miRNA sponges, particularly those that house
fluorescent reporter genes within the vector backbone
have proven to be valuable research tools to study the
impact of miRNA loss-of-function scenarios in animalmodels of carcinoma development and metastatic pro-
gression. Unfortunately, the necessity of miRNA sponges
to be stably expressed within target cells has greatly
limited their overall therapeutic value due to issues
related to the delivery of miRNA sponge retroviral parti-
cles specifically and efficiently to carcinoma cells, not nor-
mal host [119].
In stark contrast to the mechanism of action of miRNA
sponges, miRNA masks antagonize miRNA function by
binding directly to 3'-UTR sequences in target mRNAs,
thereby protecting their integrity by preventing miRNA
binding reactions [120]. Experimentally, this technique
provides an innovative approach to determine the extent
to which a given cellular phenotype is driven by distinct
miRNA:mRNA pairs. Clinically, however, this technique is
also limited by drug delivery and specificity issues, as well
as by the fact that targeting and/or protecting a single
mRNA via miRNA masks is unlikely to outperform
the delivery of miRNA sponges, which will restore and/or
protect the expression of hundreds of mRNAs in carcin-
oma cells.
miRNA overexpression strategies
“miRNA replacement therapy” has been proposed as a
novel means to restoring tumor suppressing miRNAs at
supraphysiological levels with developing and progressing
carcinomas, doing so by engineering and delivering double-
stranded 2′O-methyl phosphorothioate-containing miRNA
mimics. Indeed, the growth of lung tumors in mice was se-
verely compromised by the delivery of miRNA mimics for
let-7b and miR-34 [121], as was that of prostate tumors fol-
lowing the administration of miRNA mimics for miR-15a
and miR-16 [59]. Alternatively, the use of adenovirus-
associated vectors (AVV), which do not integrate into the
genome and are eliminated with minimal toxicity [122,123],
have also been employed to deliver and express tumor sup-
pressing miRNAs in carcinomas. Indeed, systemic adminis-
tration of AAV-miR-26a viral particles to mice bearing
hepatocellular carcinomas resulted in a dramatic reduction
in disease progression due to decreased cell proliferation
and survival [124]. However, due to the extensive alter-
ations that transpire within the miRNA processing system
in malignant cells, it may prove to be especially challenging
to achieve sustained therapeutic expression levels of tumor
suppressing miRNAs in carcinomas, particularly over long
periods of time and treatment durations.
Small-molecule inhibitors
Numerous small molecule inhibitors have been shown
to elicit global alterations in miRNA expression profiles
[5]. For instance, the administration of small molecule
inhibitors against specific oncogenic effectors, transcrip-
tion factors, or pathways can suppress the upregulated
expression of oncomiRs. Alternatively, it may be feasible
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miRNA biogenesis, thereby impacting global miRNA ex-
pression profiles. Indeed, Gumireddy et al. [125] recently
screened a luciferase-miR-21 reporter gene against chem-
ical library that contained more than 1000 compounds,
resulting in the identification of 2 small molecule inhibi-
tors against miR-21 and that prevent its binding to 3′UTR
seed sequences. Expanding similar miRNA-based reporter
screens to larger and more complex chemical libraries,
as well as to those comprised of FDA-approved drugs
(i.e., drug repurposing) holds tremendous potential in
isolating a variety of novel agents capable of inhibiting
miRNA function both experimentally and clinically.
miRNAs as biomarkers
miRNAs are normally expressed in a developmental- and
tissue-specific manner to maintain cell and tissue homeo-
stasis [126]. However, disease development disrupts this
cellular equilibrium and elicits aberrant miRNA expression
in a disease-specific manner, particularly with respect to
genetically distinct subtypes of breast cancer. In fact,
miRNA signatures have recently been observed to possess
more predictive power as compared to their larger and
more extensive mRNA signature counterparts [127]. Along
these lines, miRNA profiles are more effective in identify-
ing tumors of unknown origin than their corresponding
mRNA profiles [126]. Likewise, monitoring the presence of
circulating miRNAs has recently been undertaken as a
means to readily distinguish cancer patients from healthy
individuals, and to predict overall and relapse-free survival
rates with extreme accuracy [128]. Given the remarkable
stability of miRNAs in the circulation, tissues, and other
biological fluids, future studies clearly need to expand our
understanding and repertoire of miRNA signatures and
their specificity for diagnosing human malignancies, and
for monitoring carcinoma development, metastatic pro-
gression, and recurrence.
Conclusions
The ability of miRNAs to function as tumor promoters
or tumor suppressors is well-established, as is their role
in regulating normal tissue homeostasis and disease de-
velopment in humans. Moreover, the recent success of
miRNA-based therapies to treat HCV, coupled with the
apparent effectiveness of miRNA-targeted oligonucleo-
tides to alleviate tumor development in preclinical models
of cancer, suggests that miRNAs represent a feasible class
of targets to treat human malignancies. Likewise, pharma-
cological targeting of miRNAs will impact a plethora of
oncogenic signaling nodes and biological processes due
to the extreme range of mRNAs governed by a single
miRNA, thereby offering a unique therapeutic advantage
over current single gene/molecule-based approaches to
cancer. However, the broad spectrum of genes targeted bymiRNA-based therapeutics might also present a number
of challenges, particularly the potential for off-target
miRNA activities that could lead to unwanted toxicities.
As such, improving miRNA target prediction algorithms
and garnering a greater understanding of miRNA signal-
ing networks will aid significantly in the development of
highly specific and safe miRNA-targeted therapies. Equally
challenging are overcoming the difficulties associated with
the administration and effective delivery miRNA cargos to
tumor tissues. Although recent chemical modifications to
RNA-based structures have greatly improved their stability
and lessened their toxicities, the ability to target and de-
liver similarly modified miRNAs to tumors may neverthe-
less prove to be daunting undertaking. Thus, while the
packaging of miRNAs within nanoparticles and liposomes
may indeed improve their ultimate delivery to developing
tumor microenvironments, it is clear that future studies
need to elucidate the optimal chemistry profiles necessary
to maximize oligonucleotide delivery to malignant tissues
and cells, thereby alleviating the development, metastasis,
and recurrence of human carcinomas.
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